Analysis of Cyclophosphamide and interleukin-2 therapy for advanced renal cell carcinoma
Phase 1
- Conditions
- renal cancer
- Registration Number
- JPRN-UMIN000030321
- Lead Sponsor
- Osaka City University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 20
Inclusion Criteria
Not provided
Exclusion Criteria
1) Patients with a history of hypersensitivity to Cyclophosphamide and IL-2 2) Pregnant women, lactating women, pregnant women, lactating women, patients with a plan to go out 3) Patients receiving adrenocortical hormone drug and pentostatin 4) Patients with metastatic lesions in the brain 5) Patients who are deemed inappropriate for the subject doctor in this clinical trial
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Response efficiency in the therapy of IL-2 after preceding Cyclophosphamide
- Secondary Outcome Measures
Name Time Method 1) progression-free survival in the therapy of IL-2 after preceding Cyclophosphamide (Progression-free Survival, PFS) 2) Safety in the therapy of IL-2 after preceding Cyclophosphamide 3) On the change of various lymphocytes of peripheral blood